News Brief

Inspira Awarded $1.98M NIH Grant for Diabetes Therapy

Inspira Therapeutics was awarded a $1.98 million NIH grant to develop its polymeric biomaterial-based tolerogenic treatment for type 1 diabetes.

Gator Alumna Launches Byppocampus, an Eco-Friendly, Student-to-Student Campus Food Delivery Program

UF Innovate | The Hub resident Byppo Technologies, Gainesville’s innovative local food service platform, is partnering with Aramark, a global leader of acclaimed services in food, facilities, and uniforms, to bring a revolutionary campus dining experience to the University of Florida.

Setlow and Bizon Co-Edit Behavioural Brain Research Journal

Barry Setlow, Ph. D. and Jen Bizon, Ph.D. co-edit an invitational special issue of the Behavioural Brain Research journal titled “Amygdala and value-based decision making,” based on related previous work.

Morphogenesis Awarded SBIR Funding for Cervical Cancer Therapy

UF startup and UF Innovate | Sid Martin Biotech alum Morphogenesis, Inc., a clinical-stage biotechnology company, has obtained funding to develop a new therapeutic drug to treat cervical cancer.

UF Health First in U.S. To Implant New, Advanced Deep Brain Stimulation System

A team of University of Florida Health neurosurgeons and neurologists recently became the first in the U.S. to implant a newly FDA-approved, technologically advanced deep brain stimulation system designed to more precisely target motor symptoms of Parkinson’s disease and two other movement disorders.

New Model To Help Patients Holistically Manage Pain Established at UF Health Jacksonville

The PAMI POST-Ed program, created to help people manage pain by using a combination of traditional methods mixed with new coaching and education, has been established at UF Health Jacksonville.

entrinsic bioscience Secures $49 Million in Financing To Accelerate Development and Commercialization of Next Generation Functional Ingredients and Active Pharmaceutical Ingredients

UF startup and UF Innovate | Sid Martin Biotech resident entrinsic bioscience (EBS), a company pioneering a next-generation protein modulation technology, announced that it has secured $49 million in non-dilutive growth capital from Jefferies Group LLC's subsidiary, Jefferies Funding LLC (Jefferies).